Dai Weiwei, Zhang HongLiang, Zhong Zhendong A, Jiang Li, Chen Haiyan, Lay Yu-An Evan, Kot Alexander, Ritchie Robert O, Lane Nancy E, Yao Wei
Department of Science and Technology, Integrative Medicine Discipline, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, PR China.
Clin Orthop Relat Res. 2015 Aug;473(8):2495-504. doi: 10.1007/s11999-015-4246-5.
One of the strongest predictors for osteoporosis is peak bone mass. Interventions to augment peak bone mass have yet to be developed. β-Ecdysone (βEcd), a natural steroid-like compound produced by arthropods to initiate metamorphosis, is believed to have androgenic effects and so may be used to augment bone mass.
QUESTIONS/PURPOSES: The purpose of this study was to use both male and female (1) gonadal-sufficient; and (2) -insufficient mice to investigate sex differences in terms of bone development and structure after βEcd administration.
Two-month-old male and female Swiss-Webster mice were randomized to receive either vehicle or βEcd (0.5 mg/kg) for 3 weeks. In a separate experiment to evaluate the effects of βEcd on sex hormone-deficient mice, gonadectomy was performed in male (orchiectomy [ORX]) and female mice (ovariectomy [OVX]). Sham-operated and the ORX/OVX mice were then treated for 3 weeks with βEcd. Primary endpoints for the study were trabecular bone structure and bone strength.
In male mice, the trabecular bone volume was 0.18±0.02 in the placebo-treated (PL) and 0.23±0.02 in the βEcd-treated group (p<0.05 versus PL); and 0.09±0.01 in the ORX group (p<0.05 versus PL) and 0.12±0.01 in the ORX+βEcd group. Vertebral bone strength (maximum load) was 43±2 in PL and 51±1 in the βEcd-treated group (p<0.05 versus PL); and 30±4 in the ORX group (p<0.05 versus PL) and 37±3 in the ORX+βEcd group. In female mice, trabecular bone volume was 0.23±0.02 in PL and 0.26±0.02 in the βEcd-treated group (p<0.05 versus PL); and 0.15±0.01 in the OVX group (p<0.05 versus PL) and 0.14±0.01 in the OVX+βEcd group. Maximum load of the vertebrae was 45±2 in PL and 48±4 in the βEcd-treated group; and 39±4 in the OVX group (p<0.05 versus PL) and 44±4 in the OVX+βEcd group.
These findings suggest the potential use of βEcd in the augmentation of bone mass in growing male and female mice. It may also partially prevent the detrimental effects of gonadectomy on trabecular bone.
Our results support the potential use of βEcd or nature products that are rich in βEcd to augment peak bone mass. βEcd may differ from the other anabolic hormone treatments that may have severe side effects such as serious cardiac complications. However, its effects on humans remain to be determined.
骨质疏松症最强的预测指标之一是峰值骨量。目前尚未开发出增加峰值骨量的干预措施。β-蜕皮激素(βEcd)是节肢动物产生的一种天然类固醇样化合物,用于启动变态发育,被认为具有雄激素样作用,因此可用于增加骨量。
问题/目的:本研究的目的是使用雄性和雌性(1)性腺功能正常;以及(2)性腺功能不全的小鼠,研究给予βEcd后骨骼发育和结构方面的性别差异。
将2个月大的雄性和雌性瑞士韦伯斯特小鼠随机分为两组,分别接受赋形剂或βEcd(0.5毫克/千克)治疗3周。在另一项评估βEcd对性激素缺乏小鼠影响的实验中,对雄性(去势 [ORX])和雌性小鼠(卵巢切除 [OVX])进行性腺切除术。然后对假手术组和ORX/OVX小鼠用βEcd治疗3周。该研究的主要终点是小梁骨结构和骨强度。
在雄性小鼠中,安慰剂治疗组(PL)的小梁骨体积为0.18±0.02,βEcd治疗组为0.23±0.02(与PL相比,p<0.05);ORX组为0.09±0.01(与PL相比,p<0.05),ORX+βEcd组为0.12±0.01。椎体骨强度(最大负荷)在PL组为43±2,βEcd治疗组为51±1(与PL相比,p<0.05);ORX组为30±4(与PL相比,p<0.05),ORX+βEcd组为37±3。在雌性小鼠中,PL组的小梁骨体积为0.23±0.02,βEcd治疗组为0.26±0.02(与PL相比,p<0.05);OVX组为0.15±0.01(与PL相比,p<0.05),OVX+βEcd组为0.14±0.01。椎体的最大负荷在PL组为45±2,βEcd治疗组为48±4;OVX组为39±4(与PL相比,p<0.05),OVX+βEcd组为44±4。
这些发现表明βEcd在增加生长中小鼠骨量方面具有潜在用途。它还可能部分预防性腺切除术对小梁骨的有害影响。
我们的结果支持βEcd或富含βEcd的天然产物在增加峰值骨量方面的潜在用途。βEcd可能与其他合成代谢激素治疗不同,后者可能有严重副作用,如严重心脏并发症。然而,其对人类的影响仍有待确定。